PERSANTINE TAB 75MG TABLET

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

DIPYRIDAMOLE

Dostupné s:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

ATC kód:

B01AC07

INN (Mezinárodní Name):

DIPYRIDAMOLE

Dávkování:

75MG

Léková forma:

TABLET

Složení:

DIPYRIDAMOLE 75MG

Podání:

ORAL

Jednotky v balení:

100

Druh předpisu:

Prescription

Terapeutické oblasti:

MISCELLANEOUS VASODILATATING AGENTS

Přehled produktů:

Active ingredient group (AIG) number: 0106621003; AHFS:

Stav Autorizace:

CANCELLED POST MARKET

Datum autorizace:

2010-06-28

Charakteristika produktu

_ _
_Product Monograph _
_Page 1 of 22 _
PRODUCT MONOGRAPH
Pr
PERSANTINE
®
Dipyridamole Tablets
Dipyridamole for Injection
50 mg and 75 mg tablets
5 mg/mL injectable ampoules
Coronary Vasodilator
Inhibitor of Platelet Adhesion and Aggregation
Boehringer Ingelheim Canada Ltd.
5180 South Service Road
Burlington, ON L7L 5H4
Date of Preparation:
March 15, 1995
Date of Revision:
May 20, 2005
Submission Control No: 092334
BI BPI number: 0248-02 (tablets), 0150-04 (ampoules)
_ _
_Product Monograph _
_Page 2 of 22_
Table of Contents
[To update, right-click anywhere in the Table of Contents and select
“Update Field”, “Update
entire table”, click OK.]
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................5
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND
ADMINISTRATION................................................................................9
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND
STABILITY..........................................................................................11
SPECIAL HANDLING INSTRUCTIONS
.......................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
...........................